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Pffects of Beta-Blocker
herapy on Ventricular Repolarization
ocumented by 24-h Electrocardiography
n Patients With Type 1 Long-QT Syndrome
atti Viitasalo, MD,* Lasse Oikarinen, MD,* Heikki Swan, MD,* Heikki Väänänen, MSC,†
ere Järvenpää, MD,* Harri Hietanen, MD,* Jouko Karjalainen, MD,* Lauri Toivonen, MD, FACC*
elsinki and Espoo, Finland
OBJECTIVES We tested the hypothesis that in long-QT syndrome (LQT) type 1 (LQT1), beta-blocker
therapy may decrease both the diurnal maximal T-wave peak to T-wave end interval (TPE)
and the maximal ratio between late and early T-wave peak amplitude (T2/T1 ratio), which
are electrocardiographic counterparts of transmural dispersion of repolarization (TDR) and
early afterdepolarizations (EA), respectively.
BACKGROUND Ventricular repolarization duration and increased TDR and EAs are the three electrophys-
iological components generating the high risk of ventricular arrhythmias and sudden death in
the inherited LQT. In the most prevalent LQT1 form of LQT, treatment with beta-blockers
reduces serious arrhythmia events dramatically without a known influence on QT interval
duration. In experimental LQT1 models, beta-blockers decrease TDR and prevent EAs.
METHODS We reviewed 24-h electrocardiographic recordings obtained before and during the treatment
with beta-blockers from 24 genotyped LQT1 patients to record maximal TPE intervals and
T2/T1 ratios as well as maximal and rate-adapted QT intervals using a computer-assisted
program.
RESULTS Treatment with beta-blockers decreased the maximal diurnal T2/T1 amplitude ratio from
3.0  1.0 to 2.2 0.6 (p 0.002). Beta-blockers also decreased both maximal TPE intervals
and abrupt maximal QT intervals at heart rates higher than 85 beats/min, whereas QT
intervals measured at steady-state conditions remained unchanged.
CONCLUSIONS Prevention of abrupt increases of electrocardiographic TDR, EA, and ventricular repolarization
duration at elevated heart rates may explain the favorable clinical effects of beta-blockers in
LQT1. (J Am Coll Cardiol 2006;48:747–53) © 2006 by the American College of Cardiology
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.084Foundation
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Tong-QT syndrome (LQT) type 1 (LQT1), the most
revalent type of inherited LQT syndrome, is caused by
utations leading to decreased activity in the IKs potassium
urrent (1). As electrophysiological consequences of the
otassium ion channel mutations, ventricular repolarization
s prolonged, transmural dispersion of repolarization (TDR)
s increased, and early afterdepolarizations (EA) may appear
2). These three electrophysiological components expose
atients with LQT1 to torsades de pointes (TdP), which
ften lead to syncope or sudden death typically associated
ith physical exercise or psychological stress (3). Beta-
locker treatment has dramatically reduced cardiac events in
QT1 (4,5). Although beta-blockers’ favorable effects in
QT1 patients are expected to depend on normalization of
entricular repolarization, no consistent effect of beta-
lockers on QT interval duration has been reported so far.
n an experimental LQT1 model, on the other hand,
ropranolol had little or no effect on the duration of action
otential and QT interval, whereas during strong sympa-
From the *Department of Cardiology, Helsinki University Central Hospital,
elsinki, Finland; and the †Laboratory of Biomedical Engineering, Helsinki Uni-
ersity of Technology, Espoo, Finland. Supported by a grant from the Finnish
oundation for Cardiovascular Research, Helsinki, Finland.h
Manuscript received January 20, 2006; revised manuscript received April 6, 2006,
ccepted April 23, 2006.hetic stimulation propranolol inhibited TDR to increase
nd prevented the induction of TdP (6,7). In addition,
lthough Moss et al. (8) reported a significant reduction of
ardiac events in LQT1 patients during the beta-blocker
herapy, they observed only minimal changes in rate-
orrected QTc intervals in their patients’ rest electrocardio-
rams (ECGs). One may assume, therefore, that beta-
lockers’ clinical effects cannot be detected by measuring
nly QT intervals at rest. Of the three electrophysiological
omponents necessary to trigger and sustain TdP, TDR as
linically evaluated by the T-wave peak to T-wave end
TPE) interval (9) and EA as clinically evaluated by the
atio of U-wave (T2-wave) to T-wave (T1-wave) amplitude
10) are in LQT1 abrupt, presumably autonomically medi-
ted phenomena and therefore are suitable to be evaluated
sing ambulatory ECG recordings (11,12).
The purpose of this study was to explore the effects of
eta-blocker treatment on the dynamic ECG repolarization
ecognized by 24-h recordings in molecularly defined
QT1 patients. We hypothesized that treatment with
eta-blockers would decrease abrupt lengthening of TPE
ntervals as well as would decrease high T2-wave to
1-wave amplitude ratios in LQT1 patients. We also
ypothesized that beta-blocker treatment might decrease
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Beta-Blockers and Repolarization in LQT1 August 15, 2006:747–53brupt lengthening of QT intervals at elevated heart
ates.
ETHODS
tudy subjects. We studied 24 patients with the LQT1
enotype consisting of 10 different KCNQ1 mutations.
hirteen patients were symptomatic, and 11 were their
amily members and were so far asymptomatic (Table 1).
he patients were from consecutive series genotyped at the
elsinki University Central Hospital who had available
4-h ECG recordings both before the treatment and during
he treatment with a beta-blocker. The specific beta-blocker
sed, and the dose, was at the discretion of the treating
hysician (Table 1). The baseline ECG and 24-h recording
ere obtained at the same visit before the treatment. During
able 1. Clinical and ECG Characteristics of the Patients:
ffects of Beta-Blockers on Baseline ECG Parameters
Variables
LQT1 Patients
(n  24)
ge, yrs 23  13
en/women 8/16
ardiac events, n (%) 13 (54)
Cardiac arrest 2 (8)
Syncope 11 (46)
riggers for cardiac events, n (%)
Exercise 11 (85)
Emotion 2 (15)
eta-blocker therapy
Propranolol, n 18
Dose, mg/kg 1.9  0.9
Atenolol, n 3
Dose, mg/kg 1.1  0.3
Bisoprolol, n 3
Dose, mg/kg 0.1  0.01
Before
Beta-Blocker
Under
Beta-Blocker p Value
aseline ECG
Heart rate, beats/min 74  15 58  9 0.001
QTfc (Fridericia formula), ms 472  31 460  27 0.39
QTc (Bazett formula), ms 482  32 457  28 0.002
TPE interval in lead V5, ms 77  17 76  9 0.67
Maximal TPE interval in any
lead, ms
99  39 98  34 1.00
T-wave amplitude in lead V5,
mV
0.4  0.2 0.4  0.2 1.00
Maximal T-wave amplitude in
any lead, mV
0.6  0.2 0.6  0.2 0.77
Abbreviations and Acronyms
ECG  electrocardiogram/electrocardiographic
LQT1  long-QT syndrome type 1
LQT2  long-QT syndrome type 2
TdP  torsades de pointes
TDR  transmural dispersion of repolarization
TPE  T-wave peak to T-wave end interval(
CG  electrocardiogram/electrocardiographic; LQT1  long-QT syndrome type 1;
PE  T-wave peak to T-wave end interval.he treatment with a tolerable dose of a beta-blocker, the
econd ECG and 24-h recording were obtained. No patient
ook any other medication known to influence cardiac
epolarization. All study subjects were in sinus rhythm, did
ot show bundle-branch block, and did not have symptoms
r signs of other cardiac disease on clinical examination.
imilar normal daily activities were encouraged during both
ecordings. The ethical review committee of the institute
pproved the study, and informed consent was obtained
rom all participants.
olter monitor recordings and analyses. All study sub-
ects underwent two 24-h ECG recordings (model 8500,
arquette Electronics Inc., Milwaukee, Wisconsin). The
apes were initially analyzed with a Marquette 8000 Holter
nalysis system (version 5.8 software) to label the QRS
omplexes to normal, ventricular extrasystoles, or aberrant
omplexes. The ECG data were then transferred to a
ersonal computer for further analysis of T waves and QT
ntervals.
easurement of QT and TPE intervals and the T1- and
2-wave amplitudes. To measure the QT interval dura-
ions from the 24-h ECG recordings, we used previously
escribed methods for determination of T-wave fiducial
oints (13) and for measurement of QT intervals (14). In
his study, we determined the highest amplitude peak of the
eflections during repolarization as the peak of the T-wave.
n QT interval measurements, bifid T waves showing a time
nterval of 0.15 s between the highest peak and the later
ower peak were calculated into the QT duration (Fig. 1,
op); otherwise, the later lower peak was not included into
he QT duration (Fig. 1, middle) (15). Thus, QT interval
easurements always include T2 waves that are of higher
mplitude than T1 waves (Fig. 1, bottom).
To measure the T1 and T2 peaks of the T-wave, we
eviewed the morphology of T waves in the 24-h ECG
ecordings using the superimposed scan. We then looked
or the highest T2-wave amplitudes and highest T2/T1
mplitude ratios meeting the criteria of grade III bifid T
aves in the approach presented by Lehman et al. (15) and
rinted the samples on chart paper for detailed analysis as
escribed earlier in detail (12). Finally, we measured the
aximal T2/T1 amplitude ratios manually from the ECG
trips at the paper speed of 50 mm/s and with the amplitude
alibration of 0.1 mV/mm using modified lead V5. We
ecorded the maximal T2-wave amplitudes and maximal
2/T1 amplitude value as the mean of 5 consecutive beats
or each individual if 1.1, otherwise we used the value of
as the individual maximum (Fig. 1, bottom).
ata analyses and definitions. The QT and TPE intervals
ere analyzed by plotting all of the measured QT and TPE
alues recorded during 24 h against the preceding respective
R intervals as described previously (11,14). We first
etermined diurnal maximal QT peak, QT end, and TPE
ntervals. We also recorded maximal QT end and TPE
ntervals at different RR intervals with RR steps of 50 ms
from 500 to 700 ms) or with RR steps of 100 ms (from 700
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August 15, 2006:747–53 Beta-Blockers and Repolarization in LQT1o 1,400 ms). All of the maximal QT and TPE intervals
ere determined and checked visually by use of the unav-
raged ECG signal, with three or more consecutive accept-
ble measurements. We computed the median values of the
T peak, QT end, and TPE intervals against RR intervals
n RR steps of 10 ms. To analyze the rate dependence of the
T end intervals, we recorded these intervals at stable heart
ates in RR steps of 10 ms (14). We present the median
PE values of all beats during 24 h against RR intervals
igure 1. The measurement of QT end and T-wave peak to T-wave end
TPE) intervals as well as the T2/T1-wave amplitude ratio in cases with
ifid T waves. Vertical lines show the peak and the end of the T wave; see
ext for details. In the top panel, with an interpeak difference of 0.08 s, the
econd peak is a part of the T-wave. In the middle panel, with an interpeak
ifference of 0.2 s, the second peak is a U wave. In the bottom panel the
nterpeak difference is 0.18 s, but because the second peak is higher it is
nterpreted as a T2-wave with a T2/T1-wave amplitude ratio of 3.7.ith RR steps similarly to maximal TPE values. QThe baseline QT interval was measured in lead II from
2-lead ECGs and adjusted for heart rate using the Bazett
nd Fridericia formulas, giving QTc and QTfc values,
espectively.
All measurements and analyses were performed without
he investigator knowing the presence or absence of the
eta-blocker medication.
tatistical analyses. Data are presented as mean  SD.
omparison of the continuous variables before and during
eta-blocker therapy was performed using the Student t test
or paired data. Analysis of variance for repeated measure-
ents was used for both QT and TPE intervals with two
ithin-group variables (RR intervals and medication) to
stimate the effects of medication on QT and TPE intervals.
hese analyses were performed up to RR intervals of 600 ms
ecause of missing values at short RR intervals. Statistical
ignificance was defined as p 0.05. The SPSS version 13.0
SPSS Inc., Chicago, Illinois) was used for data analysis.
ESULTS
ffects of beta-blockers on heart rates. Beta-blockers
educed the heart rate of each study subject, confirming the
se of the beta-blocker. In 24-h recordings, both minimal
nd mean as well as maximal heart rates were significantly
ower during beta-blocker therapy than before the therapy
Table 2).
ffects of beta-blockers on repolarization parameters in
aseline ECG. Baseline QTfc intervals adjusted using the
ridericia cubic root formula did not change significantly
hen compared before and after starting beta-blocker ther-
py (Table 1). When using the Bazett square root adjusting
ormula, corresponding QTc intervals seemed to shorten
ith decreased heart rates during beta-blocker treatment,
resumably because this formula undercorrects measured
T values at low heart rates (16) (Table 1). The TPE
ntervals or T-wave amplitudes did not change after starting
eta-blocker therapy (Table 1).
ffects of beta-blockers on repolarization parameters in
4-h ECG. QT INTERVALS. Treatment with beta-blockers
ad no influence on the median QT peak or median QT
nd intervals determined at heart rate of 60 beats/min
Table 2). Beta-blocker treatment prolonged both maximal
iurnal QT peak and maximal diurnal QT end intervals
Table 2). Figure 2 shows the maximal QT end values and
he QT end values measured at stable heart rates. The figure
ighlights the behavior of the RR interval-related QT end
ntervals to prolong from the state of stable rates to maximal
omentary values that typically are associated with abrupt
eart rate accelerations. The beta-blocker treatment had
ittle effect on the QT end interval duration measured at any
pecified stable heart rates, whereas the beta-blocker treat-
ent shortened the transient maximal QT end intervals at
levated heart rates (Fig. 2). At low heart rates, the beta-
locker treatment tended to prolong the transient maximal
T end intervals (Fig. 2). Both men and women showed
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Beta-Blockers and Repolarization in LQT1 August 15, 2006:747–53imilar effects of the beta-blocker treatment on the behavior
f the maximal QT end interval (data not shown).
PE intervals. Figure 3 shows the maximal as well as the
edian TPE interval values at specified RR intervals before
nd during the beta-blocker treatment. At RR intervals of
00 ms or less (heart rates higher than 85 beats/min), the
aximal TPE interval values were shorter during the
reatment than before the treatment. At low heart rates,
QT1 patients tended to show longer maximal TPE
ntervals during the beta-blocker treatment than before the
reatment (Fig. 3). Both men and women showed similar
ffects of the beta-blocker treatment on the TPE interval
ehavior (data not shown).
2/T1 wave amplitude ratio. The treatment with beta-
lockers decreased the diurnal maximal T2-wave amplitudes
n the study group, with both men and women showing the
ame tendency (Table 2). The maximal T2/T1-wave am-
litude ratio decreased from 3.0  1.0 to 2.2  0.6 (p 
Table 2. Effects of Beta-Blockers on 24-h EC
Measure
Minimal heart rate, beats/min
Mean heart rate, beats/min
Maximal heart rate, beats/min
Median QT peak interval at heart rate of 60 beats/m
Median QT end interval at heart rate of 60 beats/m
Maximal QT peak interval, ms
Maximal QT end interval, ms
Median T-wave peak to T-wave end interval, ms
Maximal T-wave peak to T-wave end interval, ms
Maximal T2-wave amplitude, mV
Male (n  8)
Female (n  16)
Maximal T2/T1-wave amplitude ratio
Male (n  8)
Female (n  16)
Abbreviations as in Table 1.
igure 2. Maximal QT end intervals (higher two lines) and QT end
ntervals at stable heart rates (lower two lines) at specified heart rates
efore the treatment with beta-blockers (broken lines) and during the
reatment with beta-blockers (solid lines) in 24 long-QT syndrome type 1
LQT1) patients. **p  0.01 before the treatment versus during the
reatment with beta-blockers at RR intervals from 600 to 700 ms.
t
f.002), with 19 (79%) patients showing a decrease, whereas
nly 5 (21%) patients showed an increase or no change (Fig.
). In symptomatic patients (n  13) the maximal T2/T1-
ave amplitude ratio decreased from 3.6  0.8 to 2.4  0.6
p 0.003), whereas in asymptomatic patients (n 11) the
hange was not statistically significant (2.3  0.9 to 2.0 
.5, respectively; p  0.26). The maximal heart rate during
he preceding 30 s before the maximal T2/T1-wave ampli-
ude ratio was lower during the beta-blocker treatment
93  15 beats/min) than before the treatment (107  14
eats/min) (p  0.001).
ISCUSSION
ain findings. The present results show that treatment
ith beta-blockers decreases the maximal diurnal T2/T1-
ave amplitude ratio in symptomatic LQT1 patients. Beta-
lockers also decrease abrupt lengthening of both QT and
rameters in 24 LQT1 Patients
Before
Beta-Blocker
Under
Beta-Blocker p Value
47  8 43  6 0.02
74  10 64  8 0.001
132  17 114  15 0.001
s 394  24 396  27 0.61
482  26 486  26 0.12
454  38 475  42 0.02
565  54 584  62 0.03
89  12 92  18 0.29
195  57 176  66 0.09
0.57  0.26 0.36  0.18 0.001
0.51  0.31 0.34  0.18 0.12
0.59  0.25 0.37  0.19 0.003
3.0  1.0 2.2  0.6 0.002
2.5  0.8 2.0  0.5 0.10
3.3  1.1 2.4  0.6 0.008
igure 3. Maximal T-wave peak to T-wave end (TPE) intervals (higher
wo lines) and median TPE intervals, calculated from all beats (lower two
ines), at specified heart rates before the treatment with beta-blockers
broken lines) and during the treatment with beta-blockers (solid lines) in
4 long-QT syndrome type 1 (LQT1) patients. *p  0.05 before theG Pa
in, m
in, msreatment versus during the treatment with beta-blockers at RR intervals
rom 600 to 700 ms.
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bserved ECG effects of beta-blockers in LQT1 patients
emporally coincide with likely preceding sympathetic
ctivations.
As and induction of TdP in experimental LQT1 mod-
ls, T2/T1-wave amplitude ratio in LQT1 patients, and
ffects of beta-blockers. Several experimental and clinical
bservations using monophasic action potential recordings
uggest a key role for EA-induced triggered activity in the
enesis of TdP (17–19). Experimental evidence supports
he hypothesis that an EA-induced triggered response
nitiates TdP but that the arrhythmia is maintained by a
e-entrant mechanism (20–22). Inward currents through
Ca-L (23) or through sodium-calcium exchange (24) have
uggested being responsible for the development of EAs. In
ddition, experimental studies using an LQT2 model
howed that the ratio of T2/T1-wave amplitude could be
sed as an ECG parameter to predict the acute onset of TdP
10). In a recent clinical study, symptomatic LQT1 and
QT2 patients showed episodes of higher T2/T1-wave
mplitude ratios than asymptomatic patients with similar
enotypes at abruptly elevated heart rates in 24-h ECG
ecordings (12).
In this study we found that beta-blocker therapy de-
reased maximal amplitudes of high T2 waves. Also the
aximal T2/T1-wave amplitude ratios, abruptly present in
QT1 patients at elevated heart rates (12), decreased during
he beta-blocker treatment. In symptomatic patients with
he highest maximal T2/T1-wave amplitude ratios at base-
ine, this ratio during the beta-blocker treatment decreased
o similar values previously observed in asymptomatic pa-
ients (12). Supposing that the maximal T2/T1-wave am-
litude ratio is the ECG counterpart of EA (10), the present
ndings are in accordance with previous experimental stud-
es by Shimizu and Antzelevitch (6) showing that propran-
lol suppressed the induction of TdP by sympathetic stim-
igure 4. Maximal T2/T1-wave amplitude ratios during 24-h before
pre-BB) and during (post-BB) the treatment with beta-blockers in 24
ong-QT syndrome type 1 (LQT1) patients. The broken line shows the
verage values.lation in the LQT1 model. The effect of beta-blockers is eikely to be mediated by decreasing ICa-L activity as well as
y preventing catecholamines from binding to beta-
drenergic receptors (19). Recently, Nakagava et al. (25)
bserved that autonomic blockade with propranolol and
tropine prevented isoproterenol to induce transient TU-
ave abnormalities (high T2 waves) in normal subjects. In
atients with LQT1, the effect of beta-blockers on the
2-wave amplitude and on the T2/T1-wave amplitude ratio
as not been previously described.
DR in experimental LQT1 models and TPE interval in
QT1 patients: effects of beta-blockers. In experimental
QT1 models, IKs block prolongs action potential durations
omogeneously across the ventricular wall and TDR does
ot change significantly, but beta-adrenergic stimulation
ith isoproterenol increases TDR dramatically (6). This
ay be explained by a larger augmentation of IKs by
soproterenol in epicardial and endocardial cells than in M
ells, in which IKs is weaker (6). The result is abbreviation of
picardial but not of midmyocardial action potential dura-
ions, giving rise to increased TDR and prolonged TPE
ntervals. In addition, experimental studies have shown that
he TPE interval measured in precordial leads serves as an
ndex of TDR across the ventricle (6,7). In previous clinical
tudies in LQT1 patients, sympathetic stimulation with
pinephrine markedly prolonged the TPE interval (26), and
t elevated heart rates during 24-h ECG recordings LQT1
atients showed abrupt increases of the TPE interval (11).
In the present study we found that treatment with
eta-blockers diminished the abrupt prolongations of TPE
ntervals at elevated heart rates. This finding is in accor-
ance with a previous finding by Shimizu et al. (27), who,
y using rest ECGs, observed that propranolol completely
uppressed the influence of epinephrine in increasing the
ate-corrected TPE interval in LQT1 patients. Earlier
xperimental studies by Shimizu and Antzelevitch (6,7)
howed that beta-blockade inhibits the sympathetically
nduced transient prolongation of the M cell action poten-
ial duration and thus inhibits the increase of TDR.
We observed also that beta-blocker therapy tended to
rolong abrupt maximal TPE interval values at low heart
ates in LQT1 patients. In fact, the therapy with beta-
lockers changed the behavior of the maximal TPE values
rom the LQT1 type (caused by IKs defect) toward the
ehavior previously observed in LQT2 patients (with IKr
efect) (11). Because our patients showed only KCNQ1
utations, our findings may suggest that at low heart rates
he beta-blockers might have a weak decreasing effect on the
ctivity of IKr potassium channels in the presence of reduced
Ks channel activity. Previously it has been postulated that
yclic adenosine monophosphate may activate the HERG
hannel, thus beta-adrenergic blocking agents might act by
nterrupting the effect of cyclic adenosine monophosphate
n IKr channel function (28).
ffects of beta-blockers on QT interval behavior in
xperimental LQT1 models and in LQT1 patients. In
xperimental LQT1 models, therapeutic concentrations of
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Beta-Blockers and Repolarization in LQT1 August 15, 2006:747–53ropranolol had no significant effect on the QT interval
uration (6). In a large international study, Moss et al. (8)
eported that beta-blocker therapy had only minimal effects
n the QTc interval in LQT1 patients. In accordance with
revious experimental and clinical studies, we observed no
ignificant changes in the QT end interval duration
easured at stable heart rates during 24-h ECG record-
ngs. On the other hand, we observed that beta-blocker
reatment inhibited LQT1 patients to transiently show
ong QT end values at abruptly elevated heart rates. We
mphasize that in our approach, the maximal QT end
ntervals recorded at each specified heart rate typically
ssociate with abrupt, presumably autonomically medi-
ted heart rate accelerations. Thus, the effect of the
eta-blocker therapy on the QT interval in LQT1 pa-
ients may also be concentrated at occasions coinciding
ith abrupt sympathetic activations.
The present observations in LQT1 patients suggest that
reatment with beta-blockers may increase both maximal
T end and maximal TPE intervals at low heart rates. This
nding may further explain the benefits of combining the
se of continuous cardiac pacing with beta-blocker treat-
ent in high-risk patients with LQT1 syndrome (29,30).
tudy limitations. Our study compares TPE intervals,
igh T2 waves, and the behavior of QT end intervals
etermined before and during treatment with beta-blockers
n a limited number of LQT1 patients with 10 different
CNQ1 mutations. Thus, although our findings showed
hortened maximal TPE and QT end intervals and de-
reased maximal T2/T1-wave amplitude ratios, which all
re expected to be favorable signs of diminished arrhythmia
isk in LQT1 patients, the clinical significance of the
resent findings to predict the benefit of beta-blocker
reatment in LQT1 patients remains unclear until results
rom large prospective follow-up studies are available. Pos-
ible different effects of beta-blocker treatment between men
nd women need to be addressed in a separate larger study.
uring 24-h ECG recordings the patients are at their usual
aily activities, and therefore our approach leaves the
valuation of the effects of beta-blocker treatment on the
entricular repolarization during strenuous exercise be-
ond the scope of this study. The ECG measures used in
his study give only an approximation for evaluating the
lectrophysiologic effects of beta-blockers on ventricular
epolarization.
onclusions. This study shows detailed effects of beta-
locker treatment on the ECG ventricular repolarization in
atients with LQT1 syndrome. At elevated heart rates,
eta-blockers seem to decrease abrupt increases of QT
nterval durations and of TPE intervals as well as to decrease
aximal T2/T1-wave amplitude ratios. Thus, in conditions
n which preceding sympathetic activations are likely, beta-
lockers have effects on the 3 electrophysiological compo-
ents necessary to trigger and sustain TdP. These findings
re in strong accord with the clinical experience of theeduction of cardiac events in LQT1 patients using beta-
locking medication (4,5,8), giving insight on explanations
f the favorable effects of beta-blockers, particularly in this
enotype.
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epartment of Cardiology, University Central Hospital, Haart-
aninkatu 4, 00290 Helsinki, Finland. E-mail: matti.viitasalo@
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